Figure 4 | Scientific Reports

Figure 4

From: A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma

Figure 4

Antitumour effect of c4G12 in a dog with undifferentiated sarcoma. A dog with multiple metastatic lesions of undifferentiated sarcoma was treated with 5 mg/kg c4G12 every 2 weeks and the tumour burden was evaluated by computed tomography (CT). (a,c) Tumour appearance at baseline (week 0). (b,d) Tumour appearance after 3 weeks of c4G12 treatment. The tumours clearly responded to treatment on week 2, and the shrinkage was confirmed by CT on week 3. Contrast-enhanced, and matched transverse CT images were shown. Arrowheads indicate the tumour lesions.

Back to article page